Study of effectiveness of antiviral drugs (umifenovir, triazavirin) against acute respiratory viral infections

Aim. Comparative study of clinical efficacy and safety of antiviral drug triazavirin and umifenovir in the treatment of patients with acute respiratory viral infections and influenza. Methods. The study included 100 patients aged 18 to 65 years diagnosed with moderate acute respiratory viral infection. Group 1 included 34 patients receiving umifenovir 200 mg 4 times a day for 5 days, and comparison group included 32 patients who received triazavirin 1 capsule (250 mg) 3 times a day for 5 days. Group 3 (control group) included 34 patients not treated with antiviral therapy. Efficacy and safety of the studied antiviral drugs were evaluated based on clinical symptoms in the disease course and were confirmed by adaptive reactions of the organism. Results. Among patients receiving triazavirin, recovery time and fever, headache and catarrhal syndrome resolution time were less than among patients who received umifenovir. On triazavirin treatment with favorable tolerability, symptomatic medications (antipyretics) were discontinued, and the duration of their use was less, than in patients receiving umifenovir. Evaluation of clinical efficacy of umifenovir and triazavirin for the treatment of acute respiratory viral infections and influenza demonstrated that the drugs effectively reverse the main symptoms of the disease (p <0.05), reduce complications incidence (18.1±2.1% vs. 55.9±3.2%, p <0.05) and contribute to the stabilization of adaptive reactions of the organism in contrast to the results of patients not receiving etiotropic therapy (6.9±2.9% vs. 12.8±2.7, p <0.05). During the use of umifenovir by day 4 and during the use of triazavirin by day 3 intoxication and catarrhal syndromes had been reversed, while in case of the absence of antiviral therapy, 55.8% of patients had continuing intoxication and catarrhal symptoms. Conclusion. The results of the study allow defining umifenovir and triazavirin as the first line of defense against acute respiratory viral infections with good efficacy and tolerability of the drugs.

Download Full-text

Evaluation of the effectiveness of ARVI treatment regimen including etiotropic (enisamium iodide) and symptomatic treatment

Terapevticheskii arkhiv ◽

10.26442/00403660.2020.03.000572 ◽

2020 ◽

Vol 92 (3) ◽

pp. 50-55

Author(s):

D. A. Lioznov ◽

E. J. Karnaukhova ◽

T. G. Zubkova ◽

E. V. Shakhlanskaya

Keyword(s):

Influenza A ◽

Viral Infections ◽

Clinical Symptoms ◽

Randomized Study ◽

Antiviral Drug ◽

Main Group ◽

Average Score ◽

Control Group ◽

Symptomatic Therapy ◽

Respiratory Viral Infections

Aim. To assess the effectiveness of the use of the antiviral drug enisamium iodide in the complex treatment of acute respiratory viral infections (ARVI) caused by various pathogens in routine clinical practice. Materials and methods. А prospective randomized study included 134 patients who were treated in the epidemic season of influenza and ARVI in 20182019. All patients were examined for the presence of influenza A and B viruses, respiratory syncytial virus, human metapneumovirus, parainfluenza virus, coronaviruses, rhinoviruses, adenoviruses in nasopharyngeal swabs by PCR. Patients of the main group received enisamium iodide along with symptomatic therapy, the control group received only symptomatic therapy. The primary parameter of the effectiveness of therapy was evaluated on the scale of the general severity of the manifestations of ARVI (Total Symptom Score TSS) from the 2nd to the 4th day and by the secondary criteria of effectiveness: assessment of the duration of ARVI, the severity of fever, the proportion of patients with normal body temperature, the duration of the main clinical symptoms of acute respiratory viral infections, the proportion of patients in whom complications requiring antibiotics were noted, the dynamics of interferon status on the 6th day. To conduct a statistical analysis, depending on the efficiency parameter, the ANCOVA method with a fixed group factor and an initial score on the TSS severity scale was used as covariates, a criterion for comparing quantitative indicators in two independent groups. Results. According to the results of the analysis of the primary efficacy parameter, the median (interquartile range) of the average score on the scale of the general severity of ARVI manifestations in the main group was 4.33 (3.675.83), in the comparison group 6.00 (4.677.25; p0.001). The duration of systemic and local manifestations of acute respiratory viral infections was statistically significantly less in the main group (p=0.002 and p=0.019, respectively). Prescription of additional therapy was required in 2 (2.9%) patients of the main group (patients taking enisamium iodide), compared with 8 (11.9%) patients in the control group. Serum levels of interferon  and interferon  on the last day of treatment were statistically significantly higher in patients of the main group compared with the control group (p0.001). Treatment (excellent) was evaluated by 42 (62.7%) patients, while in the control group only 17 (25.8%) patients gave similar ratings. Both patients (p0.001) and doctors (p0.002) rated therapy tolerance better in the study group. Conclusion. The results confirmed the safety and effectiveness of enisamium iodide as a treatment for ARVI and influenza. The antiviral, interferonogenic and anti-inflammatory properties of the drug are involved in the formation of an antiviral response and reduce the risk of complications, which makes it possible to reduce the number of symptomatic agents used.

Download Full-text

Clinical effectiveness of the preparation Enisamium iodide in the complex treatment of ARVI

International Professional Journal Medicine ◽

10.31082/1728-452x-2020-215-216-5-6-32-37 ◽

2020 ◽

Vol 5-6 (215-216) ◽

pp. 32-37

Author(s):

Sholpan Kulzhanova ◽

◽

Gauhar Nurakhmetova ◽

Maiya Konkayeva ◽

Zauresh Smagulova ◽

...

Keyword(s):

Clinical Efficacy ◽

Viral Infections ◽

Clinical Symptoms ◽

Randomized Study ◽

Statistical Processing ◽

Control Group ◽

Symptomatic Therapy ◽

Complex Treatment ◽

Epidemic Season ◽

Respiratory Viral Infections

The list of etiotropic drugs recommended for the treatment of influenza and other acute respiratory viral infections is not very large and requires sufficient justification for rational tactics of their use. In accordance with the WHO strategy for combating influenza and SARS, it is necessary to continue research to study the clinical efficacy of antiviral drugs with a combined effect - etiotropic, pathogenetic and symptomatic. Enisamium iodide is one of such drugs for etiotropic and pathogenetic therapy of ARVI. Aim. To evaluate the clinical efficacy of the drug enisamium iodide (amizone) in the complex therapy of acute respiratory viral infections (ARVI). Material and methods. The randomized study included 40 patients who were treated during the epidemic season of influenza and ARVI 2019. Patients of the main group received enisamium iodide along with symptomatic therapy, the control group received only symptomatic therapy. The clinical efficacy of treatment was assessed by the duration of the main clinical symptoms of ARVI, the proportion of patients who developed complications requiring antibiotics. Statistical processing of the obtained data was carried out using the SPSS 12.0.2 software for Windows. Results and discussion. The results of a randomized study showed the clinical efficacy and safety of amizone (enisamium iodide) in the complex treatment of acute respiratory viral infections of various etiologies, compared with the use of only symptomatic therapy drugs. The duration of fever and the main clinical symptoms of acute respiratory viral infections were statistically significantly less in the study group than in the control group. Accordingly, the proportion of patients whose body temperature returned to normal on days 2–3 of treatment was statistically significantly higher in the group of patients taking enisamium iodide. Complications requiring antibiotic prescription have been reported only in control patients. Also, the drug was well tolerated and there were no side effects during its use. Conclusions. The results obtained confirmed that enisamium a iodide (amizon) has a good clinical effect in ARVI, reduces the likelihood of complications in patients. The high sensitivity of various respiratory viruses to the drug allows it to be used without etiological decoding of ARVI. Keywords: acute respiratory viral infections (ARVI), influenza, enisamium iodide (amizone), antiviral therapy, clinical efficacy, safety.

Download Full-text

Meta-Analysis of Clinical Efficacy and Safety of Ligustrazine in the Treatment of Idiopathic Pulmonary Fibrosis

Evidence-based Complementary and Alternative Medicine ◽

10.1155/2020/2416132 ◽

2020 ◽

Vol 2020 ◽

pp. 1-11

Author(s):

Xiaozheng Wu ◽

Wen Li ◽

Zhenliang Luo ◽

Yunzhi Chen

Keyword(s):

Idiopathic Pulmonary Fibrosis ◽

Pulmonary Fibrosis ◽

Clinical Efficacy ◽

Adverse Reactions ◽

Clinical Symptoms ◽

Gas Analysis ◽

Control Group ◽

Efficacy And Safety ◽

Arterial Blood Gas ◽

Arterial Blood

Objective. To systematically review the efficacy and safety of Ligustrazine in the treatment of idiopathic pulmonary fibrosis (IPF). Methods. The electronic literature databases (PubMed, EMbase, CNKI, WanFang database, and VIP) were retrieved through a computer to find out the randomized controlled trials (RCT) of Ligustrazine in the treatment of IPF according to the inclusion/exclusion criteria screening test. Cochrane’s bias risk table was also used to evaluate the quality of the study and to extract effective data. RevMan 5.3 was used for statistical analysis. Results. A total of 7 RCTs (a total of 366 patients, including 196 in experimental and 170 in control group). Compared with the control group, Ligustrazine could improve the clinical symptoms ([OR] = 2.20, 95% CI [1.40, 3.46], P = 0.0006 ), lung function (VC % [MD] = 3.92, 95% CI [0.68, 7.17], P = 0.02 ), (TLC% [MD] = 4.94, 95% CI [0.37, 9.52], P = 0.03 ), the pulmonary diffusion function (DLCO % [MD] = 9.12, 95% CI [5.70, 12.55], P < 0.00001 ), and arterial blood gas analysis (PaO2 [MD] = 7.11, 95% CI [1.96, 12.25], P = 0.007 ) (PaCO2 [MD] = −2.42, 95% CI [−4.36, −0.49], P = 0.01 ) of IPF patients, respectively. However, FEV1/FVC % ([MD] = 9.37, 95% CI [−1.23, 19.97], P = 0.08 ) and adverse reactions ([MD] = 0.35, 95% CI [0.02, 5.36], P = 0.45 ) were not significantly improved. Conclusion. Ligustrazine has certain clinical efficacy in the treatment of IPF, but the safety of applying it and the adverse reactions need to be further analyzed and determined. It can be considered as a new alternative and complementary medicine to be promoted and recommended for use in medical units in various countries in the world and it solved the difficult problem of conventional drug treatment of IPF; therefore, more research strength can be put in the treatment of the pathological mechanism of IPF for further exploration. The study was registered under registration number CRD42020193626.

Download Full-text

Effectiveness of antiviral drug Kagocel® in complex treatment of viral and bacterial pneumonia in hospital

Medical alphabet ◽

10.33667/2078-5631-2019-2-27(402)-14-18 ◽

2019 ◽

Vol 2 (27) ◽

pp. 14-18

Author(s):

A. F. Popov ◽

A. I. Simakova ◽

I. A. Komarova

Keyword(s):

Antibacterial Therapy ◽

Bacterial Pneumonia ◽

Viral Infections ◽

Clinical Symptoms ◽

Respiratory Infections ◽

Research Work ◽

Antiviral Drug ◽

Influenza Viruses ◽

Control Group ◽

Antibacterial Drug

Viruses that cause acute respiratory infections are currently widespread and are reported worldwide. Among the most dangerous among them are influenza viruses, with a difficult to predict course and the possibility of rapidly developing life-threatening complications that can lead to death.The purpose of the research work: to analyze the effectiveness and safety of the treatment of community-acquired viral-bacterial pneumonia in hospital patients using only antibacterial therapy as an etiotropic treatment in comparison with the combined use of antibacterial therapy and the antiviral drug Kagocel®.Materials and methods. An open, prospective comparative study was conducted (from January 1 to December 31, 2018) to study the effectiveness of monotherapy compared with combination therapy with the antiviral drug Kagocel® for 60 patients diagnosed with community-acquired pneumonia who were admitted during the period of an epidemic rise in the incidence of acute respiratory viral infections and influenza. All patients were treated in the infectious ward of the Regional Clinical Hospital No. 2, (Vladivostok, Russia). Patients were divided into 2 groups, 30 people each, comparable in age, gender and timing of admission to the hospital. The age of patients ranged from 18 to 65 years. The first group consisted of patients who received an antibacterial drug (control group) as an etiotropic therapy, the second group — those who received a combination of antibacterial and antiviral (Kagocel®) drugs (experimental group).Results. In the group of patients receiving both antibacterial and antiviral therapy with Kagocel®, there was a significant reduction in the duration of the febrile period and catarrhal manifestations compared with patients taking only antibiotics as part of etiotropic therapy. An analysis of the data showed that the use of Kagocel® in the treatment of viral-bacterial pneumonia significantly facilitates the patient’s condition during the illness, shortens the duration of the disease, reduces the duration of the main clinical symptoms of pneumonia, namely the duration of intoxication, catarrhal syndromes, and physical changes in the lungs.Conclusions. The use of the antiviral drug Kagocel® in the treatment of community-acquired viral-bacterial pneumonia leads to a more rapid relief of the main symptoms of the disease and reduces the duration of the disease. Good tolerance of the therapy, the absence of adverse reactions was noted.

Download Full-text

Treatment of acute respiratory viral infections: results of a multicenter, double-blind, placebo-controlled, randomized clinical trial

Infekcionnye bolezni ◽

10.20953/1729-9225-2020-3-178-189 ◽

2020 ◽

Vol 18 (3) ◽

pp. 178-189

Author(s):

V.V. Rafalsky ◽

◽

R.F. Khamitov ◽

T.I. Martynenko ◽

M.V. Chernogorova ◽

...

Keyword(s):

Clinical Trial ◽

Randomized Clinical Trial ◽

Viral Infections ◽

Wilcoxon Test ◽

Controlled Study ◽

Control Group ◽

Efficacy And Safety ◽

Double Blind ◽

Double Blind Placebo ◽

Respiratory Viral Infections

This multicenter, double-blind, placebo-controlled clinical trial was conducted to obtain additional data on the efficacy and safety of Anaferon for the treatment of acute respiratory viral infections (ARVI) during seasonal increase in their incidence (RCT of the Ministry of Health of Russia No 356 dated 24.07.2018; ClinicalTrials.gov Identifier: NCT03707912). Patients and methods. Between October 2018 and March 2019, a total of 204 patients aged 18 to 70 years with ARVI symptoms were included in this study within the first 24 hours of symptom onset. Patients were randomized into 2 groups: 104 individuals received oral Anaferon (should be kept in the mouth until completely dissolved and without food) according to the following scheme: 1 tablet every 30 minutes during the first 2 hours; then 3 more doses at regular intervals during the first day; then 1 tablet 3 times a day on days 2–5; 100 individuals received placebo according to the same scheme. The primary endpoint was time to resolution of symptoms of clinically diagnosed and/or PCR (polymerase chain reaction) – confirmed ARVI. Addithional endpoints included: time to resolution of symptoms of ARVI confirmed by PCR; proportion of patients with resolution of symptoms of clinically diagnosed and/or PCR-confirmed ARVI and separately PCR-confirmed ARVI; severity of clinically diagnosed and/or PCR-confirmed ARVI (assessed by ‘area under the curve’ for the total severity index); the number of antipyretic doses taken according to indications on days 1–3 of treatment (checked in the patient's diary); proportion of patients who required antibiotic treatment on days 4–7 of follow-up. To assess safety, we analyzed the incidence and type of adverse events (AEs), their severity, association with drug use, and treatment outcome. The following statistical methods were used: Fisher's exact test, Cochran–Mantel–Haenszel test, Wilcoxon test, and repeated measures ANOVA, PROC MIXED. Results. A total of 203 patients were included in the intention-to-treat (ITT) and per protocol (РР) analysis: 103 [95] individuals in the Anaferon arm and 100 [93] individuals in the Placebo arm. Patients receiving Anaferon had significantly shorter time to resolution of all ARVI symptoms than patients receiving placebo: 4.1 ± 1.6 days vs 4.5 ± 1.5 days (p = 0.032). The disease was on average 1 day shorter in patients from the experimental group compared to controls: 3.6 ± 1.5 days vs 4.6 ± 1.5 days (p = 0.007). The proportion of patients who had resolution of symptoms of clinically diagnosed and/or PCR-confirmed ARVI was significantly higher in the Anaferon arm compared to Placebo arm (p = 0.0012). Among patients with PCR-verified ARVI, treatment with Anaferon resulted in twice as frequent recovery as in the control group on day 4 (53.7% vs 26.3%) and day 7 (70.7% vs 36.8%). In the Anaferon arm, we observed shorter disease duration and higher proportion of patients recovered compared to the Placebo arm; however, patients in both groups had a similar need for antipyretic drugs on days 1–3 of treatment, as well as for antibiotic therapy. The incidence of AEs in the Anaferon and Placebo groups did not vary significantly. No AEs with a reliable association with Anaferon were registered. Conclusion. Our findings suggest high efficacy and safety of Anaferon in patients with ARVI. The best results were obtained in patients with PCR-verified diagnosis, which can be attributed to the involvement of the interferon system in the action of the drug. The results of this RCT confirm the data obtained in previous studies and long-term clinical experience of using Anaferon. Key words: acute respiratory viral infections, ARVI, treatment, effective therapy, placebo-controlled study, Anaferon, randomized clinical trial, comprehensive therapy, efficacy, safety

Download Full-text

The use of innovative domestic interferon inducer for the prevention and treatment of acute respiratory viral infections in children

Medical Council ◽

10.21518/2079-701x-2016-1-50-53 ◽

2016 ◽

Vol 1 (1) ◽

pp. 50-53 ◽

Cited By ~ 1

Author(s):

Y. L. Mizernitskiy

Keyword(s):

Clinical Efficacy ◽

Viral Infections ◽

Mechanisms Of Action ◽

Efficacy And Safety ◽

Interferon Inducer ◽

Interferon Inducers ◽

Treatment And Prevention ◽

Prevention And Treatment ◽

Respiratory Viral Infections

The article presents data on the place of the modern endogenous interferon inducers in the treatment and prevention of influenza and ARVI in children and the mechanisms of action. The focus is on the domestic antiviral innovation Kagocel which demonstrated high clinical efficacy and safety in a number of multi-center, blind, placebo-controlled studies of the treatment and prevention of ARVI/flu in children over 2 years old.

Download Full-text

EFFICACY OF KAGOCEL IN NONSPECIFIC PREVENTION OF ACUTE RESPIRATORY VIRAL INFECTIONS AND INFLUENZA

Marine Medicine ◽

10.22328/2413-5747-2019-5-3-68-76 ◽

2019 ◽

Vol 5 (3) ◽

pp. 68-76

Author(s):

Irina V. Ozerova ◽

Nikolay A. Malishev

Keyword(s):

Immune Response ◽

Viral Infections ◽

Respiratory Infections ◽

Antiviral Drug ◽

Economic Cost ◽

Antiviral Drugs ◽

High Risk Group ◽

Time Data ◽

Direct Acting Antiviral ◽

Respiratory Viral Infections

Acute respiratory viral infections (ARVI) are some of the most widely spread diseases worldwide that are of 80% of economic cost of infectious diseases. It is known that specific prophylaxis (vaccination) and, in some clinical cases, direct-acting antiviral prophylaxis are key strategies for the prevention of influenza as one of the most dangerous ARVI viruses. However, there are a number of reasons why specific prophylaxis of influenza does not entirely address the issue of prophylaxis of ARVI that are caused by more than 200 different viruses, such as formation of immune response only to vaccine influenza strains and absence of immune response to other respiratory infections, induction in the case of short-term protection, especially, in the aged and others. Prevention of influenza with antiviral drugs is limited by risks of development of resistant influenza strains aa well as contraindications and limitations of use. Therefore, the use of nonspecific drugs such as broad-spectrum antiviral drugs of interferon type (IFN) and their inducers (II), as well as sanitary and hygienic measures is recommended for prevention. For the purpose of prevention, the use of inducers of endogenic interferons is relevant in unvaccinated persons during pre-epidemic and epidemic ARVI periods; in high-risk group (students, medical professions, transport workers, elderly, patients with comorbid pathologies, people in structured organizations, for example, military personnel), in immunocompromised people. One of the most extensively studied interferon inducers widely used in clinical practice since 2003 for prevention and treatment of influenza and diseases caused by Herpesviruses is an antiviral drug Kagocel®. The paper presents real-time data of the preventive efficacy of Kagocel® in the therapy of acute respiratory viral infections and influenza caused by different viral strains including pandemic ones.

Download Full-text

The current course of acute respiratory infections and the possibility of pathogenetic therapy.

Medical Council ◽

10.21518/2079-701x-2018-20-14-16 ◽

2018 ◽

pp. 14-16 ◽

Cited By ~ 1

Author(s):

S. B. Krutikhina ◽

E. A. Yablokova

Keyword(s):

Clinical Efficacy ◽

Viral Infections ◽

Respiratory Infections ◽

Age Groups ◽

Cold Season ◽

Medical Community ◽

Efficacy And Safety ◽

Pathogenetic Therapy ◽

Adults And Children ◽

Respiratory Viral Infections

Acute respiratory viral infections (ARVI) are leading in the structure of the general morbidity of the population. To date, more than 200 viruses that affect the respiratory tract and ENT organs are known [1]. The reservoir of ARVI pathogens is only human, the highest incidence is observed in the cold season [8]. It is also possible to infect several ARVI pathogens together, which is accompanied by a severe course of the disease and the addition of bacterial complications [6, 7]. To date, prevention and treatment of ARVI, both in adults and children, is one of the important tasks facing the medical community [1, 2]. The etiotropic therapy of most ARVI has not been developed, and the use of interferon preparations and interferon synthesis inducers has not proved their clinical efficacy [11]. As an alternative, bioregulatory agents that have proven their safety and clinical efficacy can be used [12]. The article presents numerous studies of clinical efficacy and safety of the bioregulatory drug Engystol in different age groups.

Download Full-text

OPTIMIZING ANTIVIRAL THERAPY FOR СORONAVIRUS DISEASE 2019 (COVID-19) IN CHILDREN

PEDIATRIA Journal named after G N SPERANSKY ◽

10.24110/0031-403x-2021-100-3-208-218 ◽

2021 ◽

Vol 100 (3) ◽

pp. 208-218

Author(s):

G.P. Martynova ◽

◽

M.A. Stroganova ◽

Ya.A. Bogvilene ◽

V.A. Akhmetova ◽

...

Keyword(s):

Antiviral Therapy ◽

Clinical Symptoms ◽

Nasal Congestion ◽

Main Group ◽

Control Group ◽

Interferon Α ◽

Efficacy And Safety ◽

Igg Antibodies ◽

Local Use ◽

Rectal Suppositories

The aim of the research is to study of the efficacy and safety of VIFERON® drug, rectal suppositories (interferon α-2b) 1,000,000 IU and 3,000,000 IU, and VIFERON®, gel for external and local use (interferon α-2b) 36,000 IU/g , in the complex therapy of a сoronavirus disease 2019 (COVID-19) in children. Materials and methods of research: as part of the open multicenter prospective controlled non-randomized study, 140 patients aged 1 to 17 years with the сoronavirus disease 2019 (COVID-19) were examined, and hospitalized in the infectious diseases hospital (Krasnoyarsk interdistrict clinical hospital № 1) in Krasnoyarsk from 20.04.20 to 1.08.20. Depending on the conducted antiviral therapy, the observed patients were divided into 2 groups: the main (70 people) and control (70 people). Starting from the moment of hospitalization, the main group of patients in the complex therapy received the preparation of interferon (IFN) α-2b with antioxidants (vit E and C), rectal suppositories, and IFNα-2b, gel for external and local use, according to the proposed schemes depending on age; patients of the control group were prescribed Umifenovir (Arbidol®) in age-specific dosages. The criteria of effectiveness of the therapy were the period of treatment of the main clinical symptoms of the disease (cough, nasal congestion, runny nose, sore throat, conjunctivitis, taste and smell impairment, abdominal pain, diarrhea, etc.), elimination of viral antigen in samples from the nasopharynx and feces, product dynamics of IgM and IgG antibodies to SARS-CoV-2 in the blood serum. Results: the clinical efficacy and safety of high dose polytherapy of IFNα-2b with antioxidants, rectal suppositories in combination with IFNα-2b with antioxidants, gel for external and local use in the therapy of COVID-19 in children were confirmed. Since the appointment of therapy in patients of the main group, in comparison with the control group, the time for relief of the main clinical symptoms of COVID-19 has been statistically significantly reduced: nasal congestion – from 7 to 3 days (p=0,0001), sore throat – from 7 to 3 days (p=0,0001), hyperemia in the oropharynx – from 10 to 5 days (p=0,0001), mild cough – from 7 to 5 days (p=0,05), catarrhal conjunctivitis – from 5 to 3 days (p=0,012), smell disorders – from 10 to 4 days (p=0,001) and taste – from 10 to 4 days (p=0,001). The period of complete relief of all clinical symptoms according to the «total score» was statistically significantly reduced from 9 days in the control group to 5 days in the main group (p=0,05). The elimination time of SARS-CoV-2 from the nasopharynx was also statistically significantly reduced by 5 days in the main group of patients (p=0,05). In patients receiving increased doses of IFNα-2b with antioxidants, intestinal sanitation occurred 2,5 times more frequent, statistically significant increase in the level of IgG antibodies to SARS-CoV-2 was detected in comparison with patients of the control group (p=0,05). No adverse events were recorded in the observed patients of both groups. Conclusion: the proven efficacy and safety of combined antiviral therapy with IFNα-2b with antioxidants, rectal suppositories in combination with IFNα-2b with antioxidants, gel for external and local use, are the basis for its widespread implementation into pediatric practice for the treatment of patients with сoronavirus disease 2019 COVID-19.

Download Full-text

Treatment of influenza and other acute respiratory viral infections in patients with diabetes mellitus

Terapevticheskii arkhiv ◽

10.26442/00403660.2019.10.000333 ◽

2019 ◽

Vol 91 (10) ◽

pp. 39-47 ◽

Cited By ~ 1

Author(s):

I G Sitnikov ◽

V Kh Fazylov ◽

E V Silina

Keyword(s):

Diabetes Mellitus ◽

Antiviral Therapy ◽

Viral Infections ◽

Clinical Performance ◽

Drug Prescription ◽

Antiviral Drug ◽

Hypoglycemic Agents ◽

Oral Hypoglycemic Agents ◽

Patients With Diabetes ◽

Respiratory Viral Infections

Purpose of the study. The study of the influenza and ARVI clinical performance, the development of patients with diabetes mellitus, evaluation of the effectiveness and safety application of antiviral therapy, carried out in the framework of routine clinical practice. Materials and methods. 126 patients aged from 22 to 83 years (27.8% of men) with ARVI or influenza that occurred with medical care during the first 5 days of the disease (60.3% in the first 48 hours) are included. All patients suffer from diabetes, for the treatment of which oral hypoglycemic agents or insulins were constantly taken. The patients were divided into two groups: the first group received standard symptomatic treatment of ARVI; antiviral drug Kagocel. Results and conclusion. Diabetes and other acute respiratory viral infections. There is an increase in the incidence of bacterial complications - 2.2 times, an increase in the frequency of systemic antibiotics - 2.3 times. The purpose of the drug prescription led to a more rapid regression of all the symptoms of influenza and ARVI, but the most striking positive dynamics was observed in the symptoms of general weakness and headache. The prescription of Kagocel was accompanied by a 58% reduction in the number of bacterial complications and a 53% reduction in the use of antibiotics, which led to a reduction in the number of cases of the disease and an improvement in initial diseases, with an frequency increase in 1.8 times. The most significant effect achieved with early treatment and early initiation of antiviral therapy (in the first 48 hours of the disease).

Download Full-text